Managers / Q2 2025 · view latest →
Altium Capital Management LLC
CIK 0001746382 · 152 W 57 ST FL7, NEW YORK, NY, 10019 · 2124842711
Reported Value
$0
Q2 2025
Positions
1
Filings on Record
25
2019–present window
Filed
Aug 7, 2025
original filing
Summary
Compared with Q1 2025, the fund opened 1 new position and exited 23.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
Composition data arrives with ticker enrichment.
Quarter-over-Quarter Changes full breakdown →
vs Q1 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| None | NEW | +0 | 0 | +$0 | $0 |
| ZVRAZEVRA THERAPEUTICS INC | SOLD OUT | −1.29M | 0 | −$10M | $0 |
| ALNYALNYLAM PHARMACEUTICALS INC | SOLD OUT | −25.0K | 0 | −$7M | $0 |
| EOLSEVOLUS INC | SOLD OUT | −296.2K | 0 | −$4M | $0 |
| XTNTXTANT MED HLDGS INC | SOLD OUT | −7.25M | 0 | −$3M | $0 |
| AVADEL PHARMACEUTICALS PLC | SOLD OUT | −419.1K | 0 | −$3M | $0 |
| XENEXENON PHARMACEUTICALS INC | SOLD OUT | −69.7K | 0 | −$2M | $0 |
| CTNMCONTINEUM THERAPEUTICS INC | SOLD OUT | −303.9K | 0 | −$2M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2025
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $42M | 19 | May 1, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $25M | 18 | Feb 6, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $628,262 | 1 | Nov 4, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $42M | 24 | May 13, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2024 | $353M | 67 | Feb 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $340M | 79 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $245M | 68 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $253M | 72 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $147M | 66 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $192M | 72 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $132M | 68 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $180M | 91 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $197M | 94 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $273M | 134 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $250M | 127 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $299M | 118 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $363M | 133 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $381M | 124 | Nov 17, 2021 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2021 | $431M | 135 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $360M | 124 | May 6, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $266M | 98 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.